Company: Silence Therapeutics (SLN)
Date: 11th November 2020
Time: 5pm - 6pm
Presenter: Mark Rothera, President and CEO
Company Information: Silence Therapeutics is developing a new generation of medicines by harnessing the body’s natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet medical need. Silence’s proprietary technology can be used to engineer short interfering ribonucleic acids (siRNAs) that bind specifically to and silence, through the RNAi ...